AstraZeneca faces $278M Imfinzi patent infringement lawsuit from co-developer Ono

Japanese drugmaker Ono Pharmaceutical is taking AstraZeneca to court on claims that the blockbuster lung cancer med Imfinzi flouts its PD-L1 patents. It’s a strategy that’s successfully triggered payouts from Merck & Co. and Roche in the past—and, this time, Ono is demanding even more in royalty back pay.